Moderate-to-Severe Plaque Psoriasis research hub
12 indexed studies · 10 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
This study is testing an investigational medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis. As an extension study, it tracks participants over a longer period to see if the treatment remains safe, is well tolerated by the body, and keeps skin clear of psoriasis plaques over time.
Spain · Germany - recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. It compares ESK-001 to a common treatment (Otezla) and a dummy pill (placebo) to see how well it works and if it's safe.
Bulgaria · Belgium · Portugal - recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Poland · Germany · Spain - recruitingTherapeutic use (Phase IV)
A Mono-Center, Prospective Biomarker Study to investigate the differences in the inflammatory gene expression signature, the distribution of immune cells, psoriasis-driving factors and signaling molecules between classic and hard-to-treat psoriasis plaques and the effects of TYK2 blockade with deucravacitinib – MED-PSO
This study looks at how a new medicine, SOTYKTU, affects moderate to severe plaque psoriasis. Researchers want to understand if it changes how certain genes work and how immune cells behave in different types of psoriasis patches, especially those that are usually hard to treat.
Germany - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, Zasocitinib (TAK-279), for people with moderate to severe plaque psoriasis. It compares it to an existing medicine, Deucravacitinib (SOTYKTU), and a dummy pill to see how well it works, if it's safe, and how people tolerate it.
Czechia · France · Bulgaria - recruitingTherapeutic confirmatory (Phase III)
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
This study looks at a new medicine called deucravacitinib for people with moderate to severe plaque psoriasis. It aims to see if it's safe and effective over a long period. This is a follow-up study for people who have already tried the medicine.
Hungary · Germany · Sweden - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is looking into a new tablet called SCD-044 for people aged 18 and over with moderate to severe plaque psoriasis. It wants to see if different doses of this tablet can improve skin more than a dummy pill (placebo) after 16 weeks, and if it's safe to use.
Poland · Estonia - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis
This study is testing a new drug, TAK-279, for people with moderate to severe plaque psoriasis. We want to see if it's safe and effective compared to a known treatment (Otezla) and a dummy pill (placebo) to help clear up skin patches.
Poland · Italy · Germany - recruitingTherapeutic confirmatory (Phase III)
A Phase 3B, Multi Center, Open-label Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis
This study looks at a medicine called apremilast (Otezla) for young people aged 6 to 17 with moderate to severe psoriasis. It's a long-term study to see how safe and effective the medicine is, and how it affects their growth and development.
Spain · Czechia · Belgium - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ZASOCITINIB (also called TAK-279), for people with moderate to severe plaque psoriasis. It compares the new medicine to existing treatments like Otezla and a dummy pill (placebo) to see how well it works and if it's safe.
Germany · Poland · Latvia - recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine called bimekizumab for teenagers with moderate to severe plaque psoriasis. We want to understand how it works in the body, if it's safe, and if it helps improve their skin. It's an important step in finding better treatments.
Poland · Germany - active not recruitingPHASE3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
This study looks at how a new medicine, bimekizumab, affects skin cells in people with moderate to severe psoriasis. We're trying to understand how the medicine works at a very detailed level in both psoriasis and psoriatic arthritis.
United States · Germany · Poland